Interpace Diagnostics Joins the Fight Against Pancreatic Cancer at the Pittsburgh PurpleStride Event - Nasdaq

Interpace Diagnostics Joins the Fight Against Pancreatic Cancer at the Pittsburgh PurpleStride Event Nasdaq The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ... and more »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tRgPSf
via IFTTT